August 24, 2021 -- Shape Therapeutics and Roche have inked a strategic collaboration and licensing agreement to develop gene therapies for Alzheimer's disease, Parkinson's disease, and rare diseases.
Specifically, Shape will utilize its RNAfix RNA editing platform and potentially its AAVid platform for next-generation adeno-associated viruses (AAV) to develop gene therapies. Shape will conduct preclinical research to identify and deliver development candidates discovered by its artificial intelligence-based platforms. Roche will handle development and worldwide commercialization of any products resulting from the collaboration.
Under the deal, Shape will receive an initial payment and be eligible for development, regulatory, and sales milestone payments for a potential aggregate value of over $3 billion. In addition, Shape will be eligible to receive tiered royalties on future product sales resulting from the collaboration.